Arthneeti
All Q2 FY27 results →
P&

Procter & Gamble Health Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Procter & Gamble Health Q2 Results 2026 (FY27) statement: Revenue & Margins

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Price₹5,828
Market cap₹9.7K Cr
P/E29.0
Updated2 Nov 2026
Read2 min read

Procter & Gamble Health Ltd Q2 FY27 key numbers

Revenue
Revenue from Operations for the quarter ended September 30, 2026, is ₹38,249 lakhs.

As stated in Procter & Gamble Health Ltd's Q2 FY27 results statement · published 2 Nov 2026. Reported figures, not investment advice.

Based on Procter & Gamble Health Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

The short version

Revenue from Operations for the quarter ended September 30, 2026, is ₹38,249 lakhs (Page 4). - Corresponding quarter ended September 30, 2025, revenue was ₹32,492 lakhs, showing a year-on-year increase of ₹5,757 lakhs or approximately 17.7%. - Total income (including other income) for the quarter is ₹38,638 lakhs vs. EBITDA for the quarter ended September 30, 2026: ₹15,620 lakhs

From Procter & Gamble Health Ltd's Q2 FY27 earnings-call transcript · updated 2 Nov 2026.

Revenue & Sales Performance

- Revenue from Operations for the quarter ended September 30, 2026, is ₹38,249 lakhs (Page 4). - Corresponding quarter ended September 30, 2025, revenue was ₹32,492 lakhs, showing a year-on-year increase of ₹5,757 lakhs or approximately 17.7%. - Total income (including other income) for the quarter is ₹38,638 lakhs vs. ₹32,987 lakhs in the prior year quarter. In summary, the presentation reports a 17.7% YoY revenue increase for Q2 2026.

Profitability & Margins

See what Procter & Gamble Health Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The only related financial activity mentioned is: - Purchase and construction of property, plant & equipment and capital work-in-progress: ₹968 lakhs for the six months ended September 30, 2026 (up from ₹599 lakhs in the corresponding period of 2025).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Procter & Gamble Health Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Procter & Gamble Health Ltd said on order book & pipeline — free account, 30 seconds.

Procter & Gamble Health Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹382 Cr, net profit ₹112 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What P & G Health Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Akums Drugs (Q2 FY27)

    Q2 FY27 revenue reported at ₹1,342 crore, up 31.9% YoY from ₹1,018 crore in Q2 FY26 (Page 12, 10). Key investor presentation takeaways from Akums Drugs & Pharma

  • Sai Parenteral's (Q2 FY27)

    Q2FY27 Revenue from Operations: ₹196.1 crore, up 257.4% YoY from ₹54.9 crore in Q2FY26 (Page 56). Key investor presentation takeaways from Sai Parenterals Ltd's

  • Accretion Pha. (Q2 FY27)

    25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Sigachi Indust. (Q2 FY27)

    Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Procter & Gamble Health Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Procter & Gamble Health Ltd Q2 FY27 results?

Revenue from Operations for the quarter ended September 30, 2026, is ₹38,249 lakhs (Page 4). - Corresponding quarter ended September 30, 2025, revenue was ₹32,492 lakhs, showing a year-on-year increase of ₹5,757 lakhs or approximately 17.7%. - Total income (including other income) for the quarter is ₹38,638 lakhs vs. EBITDA for the quarter ended September 30, 2026: ₹15,620 lakhs

What is Procter & Gamble Health Ltd share price analysis?

Procter & Gamble Health Ltd currently shows a neutral. The stock trades at a P/E of 29.0 with a market cap of ₹9,674 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Procter & Gamble Health Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.